Non-small cell lung carcinoma genotype(s)-EGFR Posts on Medivizor
Navigation Menu

Non-small cell lung carcinoma genotype(s)-EGFR Posts on Medivizor

Is combined treatment with erlotinib and bevacizumab effective in non-small cell lung cancer?

Posted by on May 18, 2019 in Lung cancer | 0 comments

In a nutshell This study investigated the effectiveness of erlotinib (Tarceva) and bevacizumab (Avastin) compared ti erlotinib alone in non-small cell lung cancer (NSCLC). They found that combined treatment improved survival after 12 months. Some background Non-small cell lung cancer (NSCLC) is a common type of lung cancer (LC)....

Read More

Erlotinib in patients with non-small cell lung cancer

Posted by on Dec 11, 2018 in Lung cancer | 0 comments

In a nutshell This study wanted to find out if using the medication erlotinib (Tarceva) in patients with non-small cell lung cancer improved survival. The study found that using erlotinib was safe, and may reduce the need for radical surgery in patients with non-small cell lung cancer. Some background Epidermal growth factor receptor (EGFR) is...

Read More

Looking for patients with a KRAS or EGFR mutation to test a combination of MEK162 with erlotinib

Posted by on Apr 12, 2017 in Lung cancer | 0 comments

In a nutshell This phase I/IB trial aims to determine whether combining MEK162(ARRY-162) and erlotinib (Tarceva) is safe and effective at treating patients with stage IV non-small cell lung cancer (NSCLC) with KRAS or EGFR mutations and no curative treatment options. The main outcome of the trial will be maximum tolerated dose (MTD – highest dose...

Read More

Treating NSCLC in clinical practice

Posted by on Jul 2, 2016 in Lung cancer | 0 comments

In a nutshell This review aimed to provide updated guidelines on treating non-small-cell lung cancer depending on the genetic profile of the cancer. The authors conclude that in certain types of cancers with genetic mutations (changes) drugs aimed at the specific mutation could be more beneficial than chemotherapy and other treatments. Some background...

Read More

Updated guidelines for the treatment of stage IV NSCLC

Posted by on May 30, 2016 in Lung cancer | 0 comments

In a nutshell The American Society of Clinical Oncology (ASCO) gathered a panel of experts to update guidelines on systemic therapy (such as chemotherapy) for stage 4 non-small cell lung cancer (NSCLC). They provided updated guidelines with recommendations for first, second and third-line systemic therapy as well as targeted therapy.  Some...

Read More

Is erlotinib effective in caucasian patients with EGFR-mutation-positive non-small cell lung cancer?

Posted by on Apr 25, 2016 in Lung cancer | 0 comments

In a nutshell This study aimed to assess the effectiveness of the anti-cancer drug erlotinib (Tarceva) in treating advanced non-small cell lung cancer (NSCLC) with positive EGFR mutations in caucasian patients. The study concluded that erlotinib was safe and effective as first-line treatment in this type of cancer. Some background A mutation...

Read More